Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) and Biomea Fusion (NASDAQ:BMEA – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Profitability
This table compares Amylyx Pharmaceuticals and Biomea Fusion's net margins, return on equity and return on assets.
Get Amylyx Pharmaceuticals alerts:| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -172.54% | -93.56% |
| Biomea Fusion | N/A | -45.62% | -42.69% |
Earnings and Valuation
This table compares Amylyx Pharmaceuticals and Biomea Fusion's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $280,000.00 | 8,670.59 | -$87.93 million | N/A | N/A |
| Biomea Fusion | N/A | N/A | -$41.57 million | ($2.44) | -3.91 |
Institutional & Insider Ownership
70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Biomea Fusion shares are owned by institutional investors. 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 45.7% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Amylyx Pharmaceuticals and Biomea Fusion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Biomea Fusion | 0 | 0 | 2 | 0 | 3.00 |
Amylyx Pharmaceuticals currently has a consensus price target of $48.20, indicating a potential upside of 31.55%. Biomea Fusion has a consensus price target of $25.00, indicating a potential upside of 162.33%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Amylyx Pharmaceuticals.
Summary
Biomea Fusion beats Amylyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About Amylyx Pharmaceuticals
(Get Rating)
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Biomea Fusion
(Get Rating)
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.